Cerecor, a complete human monoclonal antibody CERC-002, has received timely approval by the U.S. Food and Drug Administration (FDA) for the treatment of COVID-19 patients who are hospitalized.
CERC-002 is an anti-LIGHT treatment authorized for Kyowa Kirin that targets TNFSF14 ( Tumor necrotic factor superfamily member14) in the body.
This speedy authorization has helped researchers to find the treatment for critical diseases with unfulfilled medical needs and demands. It aids in the invention and assessment of such medications, allowing for the marketing of the approved products as quickly as possible.
A BLA (Biologic License Application) for this antibody therapy would be acceptable now for both regular registration and priority assessment, according to Cerecor.
CERC-002 has now been designed to treat severe pediatric Crohn’s disease and Covid-19 related ARDS ( Acute Respiratory Distress Syndrome) triggered by cytokines.
In another event, the government of Bolivia has agreed to purchase 15 million units of COVID-19 vaccine from Johnson&Johnson.
Reuters reported according to the agreement, the vaccine will be manufactured by a different manufacturer, and Bolivia will request WTO to waive off the vaccine’s patent.
The government stated that it has already applied for a WTO vaccine disclaimer so that Biolyse pharmaceuticals, a Canadian firm, can start the production of the Covid vaccine.
In a press conference, Benjamin Blanco, the Bolivian trade official said, “Getting someone who can make us vaccines without patents is the first step, the second is the notification to the WTO to start the (patent waiver application) process, and if that is granted, production would begin in three to six months.”
Johnson & Johnson has reached an agreement with Biolyse Pharma to manufacture a single-dose medicine that will cost around $3-$4 per unit, according to Blanco.
The United States issued a statement last week, expressing President Joe Biden’s support to temporarily suspend the intellectual rights on coronavirus vaccination, a move that was backed by nearly 120 countries.
